Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090)

Journal Article (Journal)

In the footnote of Figure 5 “Empagliflozin 0/4687 vs placebo 1/2333 participant reported Fournier's gangrene (perineal necrotizing fasciitis)” has been replaced with “Empagliflozin 0/4687 vs placebo 0/2333 participants reported Fournier's gangrene (perineal necrotizing fasciitis)”.

Full Text

Duke Authors

Cited Authors

  • Herrington, WG; Preiss, D; Haynes, R; von Eynatten, M; Staplin, N; Hauske, SJ; George, JT; Green, JB; Landray, MJ; Baigent, C; Wanner, C

Published Date

  • January 1, 2020

Published In

Volume / Issue

  • 13 / 4

Start / End Page

  • 722 -

Electronic International Standard Serial Number (EISSN)

  • 2048-8513

International Standard Serial Number (ISSN)

  • 2048-8505

Digital Object Identifier (DOI)

  • 10.1093/CKJ/SFZ009

Citation Source

  • Scopus